"It’s not surprising, then, why Pei gives BLCT an Outperform (i.e. Pear Therapeutics, Inc. (PEAR), is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need. Will they go even higher? Since that date, the stock is up another 48.3%, but Burry said Thursday he's still convinced the Tesla story will ultimately end poorly.> Well, my last Big Short got bigger and Bigger and BIGGER too....$TSLA $60 billion increase in market cap today alone...1 GM, 2 Hersheys, 3 Etsys, 4 Dominos, 10 Vornados...enjoy it while it lasts. Michael Burry, who was depicted by Christian Bale in 2015's "The Big Short," said he was shorting Tesla Inc (NASDAQ: TSLA) in December. https://www.businesswire.com/news/home/20200519005586/en/, IMF board, citing increased credit exposure risks, raises reserve target, Supreme Court agrees to hear biofuel waiver case, Twitter Permanently Bans President Donald Trump’s Account, World Bank chief, a Trump appointee, 'deeply appalled' by storming of Capitol, Google Pulls Parler, Apple May Follow, After Use in Capitol Riot, 2 Stocks That Are Flirting With a Bottom; Analysts Say ‘Buy’, Michael Burry To Tesla Investors: 'Enjoy It While It Lasts', Man Who Bought Netflix at $7.78 Says Buy This Now. The trade represented a $609,984 bearish bet. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. What are the fastest-growing stocks to watch for Q4 earnings season? We believe current investor expectations assign material value to potential best-in-class profile of ORIC-101 and skills of management.” Overall, ORIC shares get a unanimous thumbs up from the analyst consensus, with 3 recent Buy reviews adding up to a Strong Buy rating. "Tesla's stock trades around $878 at publication time.See more from Benzinga * Click here for options trades from Benzinga * Tesla Option Traders Are Dumping Massive Amounts Of Calls * What A Democratic Victory In Georgia's Runoff Election Means For The Stock Market(C) 2021 Benzinga.com. Pear Therapeutics raised $80 million in funding, which it plans to use as part of a push for coverage of its digital therapeutics. United States Software Companies (Top 10K). Nio's American depositary receipts rose 8.6% to end at a record $58.92. reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April.. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader.Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the underlying stock.Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there's no surefire way to determine if an options trade is a standalone position or a hedge. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Target-date funds will soon include annuities and maybe even private equity, as the $1.5 trillion industry tries to improve retirement security. All rights reserved. Novartis. The earnings were strong enough to support a solid dividend of 45 cents per share – and the company announced a special dividend payment, of 15 cents, to be paid in three installments during 2021. BLCT sees positive feedback as it ramps up monetization efforts, and we expect its overseas revenue contribution to increase to 21% in ‘22E. Multiple Conversion Price % Owned; Series D-2: 0,000,000: 00.000000: 00: 00.00: 00.00: 00: The gains come as investors are feeling confident. For more information, visit Pear at www.peartherapeutics.com. And he just went public with what he predicts will be his next big winner. Tag: Pear Therapeutics. Benzinga does not provide investment advice. The stock is priced at $32.91, while the $50.67 average price target indicates room for an ~54% growth. Pear said PDTs are a new therapeutic class that uses software to directly treat serious disease, alone or in combination with drugs. Pear Therapeutics, Inc. today announced publication of real-world data analyzing healthcare resource utilization for reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD), in the peer-reviewed journal Expert Review of Pharmacoeconomics & Outcomes Research. We expect that equity markets will remain sensitive to developments tied to the pandemic that have held the US and global economy hostage for nearly a year," Stoltzfus said.The second-biggest news, but the one most likely, in Stoltzfus’ view, to make an impression on the market, is the Georgia election. The current membership paying ratio is significantly lower than peers'. Active, Closed, Last funding round type (e.g. The firm's analysts have tagged three stocks that they see gaining upwards of 80% for the year ahead. Novartis has moved into the emerging digital therapeutics sector through a deal (PDF) with the pioneering Pear Therapeutics. PDTs directly treat diseases, demonstrate safety and efficacy in randomized clinical trials, receive labeled claims from FDA, and are available only by prescription. We think there is very little downside to NOI from the legacy book, and view any realizations and re-deployments as a big positive to the stock.”O’Shea gives Apollo an Overweight (i.e. ""So these guys are dancing they are in rhythm they're in flow let them do their thing. Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway. Pear Therapeutics is proud to have a group of investors that represent the unique composition of the company, spanning biotech, technology and pharma. Apollo has investments in 147 companies, with average exposure of $15.9 million. The Dow Jones Industrial Average traded slightly lower in today's stock market after the major indexes all hit fresh record highs the day prior. get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors. The initiative includes several aspirational goals, including getting 6 million hydrogen fuel cell cars on the road, building 1,200 hydrogen refueling stations and producing 5 million tons of hydrogen fuel annually by 2040.Plug is both a hydrogen producer and a fuel cell maker, and South Korea could potentially be a massive new customer over the next 20 years.The news also triggered a wave of bullish analyst commentary on Wall Street. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. GSBD is a subsidiary of Goldman, and focuses on mid-market companies, providing closed-end management investment services and middle-market credit access.GSBD’s share performance in 2020 showed a steady rebound from the initial recession caused by the corona crisis last winter. These stocks, whose prices are hitting bottom, present investors with a choice and an opportunity. The funds raised will be used to pay down the revolving credit facility, improving interest on existing debt.Also in November, GSBD reported 80 cents EPS for the quarter ending September 30. With an average price target of $121, investors stand to take home a 33% gain, should the target be met over the next 12 months. “Strayer U. continues to see declining new enrollments given its student demographics (e.g., undergraduate, first-time college students) are being disproportionately hurt during the pandemic. Apple Inc. (NASDAQ: AAPL) and Hyundai Motor Company (Pink: HYMTF) are exploring partnering on self-driving electric vehicles, according to Bloomberg. In his campaign, Joe Biden promised to roll back Trump’s tax policies, and to enact a series of large spending initiatives. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The latest financing was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative and EDBI. At the end of the first day’s trading, BLCT closed at $23.43; since then, however, the stock has fallen ~60%.Covering the stock for Oppenheimer, analyst Bo Pei sees a clear path forward to greater profits, and believes the current low price is a buying opportunity. In his first note of the new year, Stoltzfus notes a series of factors that are going to impact the markets. And a growing group of them, including some in the S&P 500, are actually seen putting up huge profit growth this year. (To watch Gershell’s track record, click here)Backing his stance, Gershell says, “Recent Viridian acquisition and $91M raise set miRagen on a new course, as the incoming programs position it to compete in the fertile thyroid eye disease market… we see ample revenue potential for [VRDN-001], and its higher potency may enable differentiation... We expect that progress in the development of MGEN's TED candidates will support outperformance.” Overall, Wall Street likes the risk/reward factor at play here, as TipRanks showcases a Strong Buy consensus rooting for MGEN's success. Pear Therapeutics today announced the filing of a submission to the U.S. Food and Drug Administration (FDA) seeking marketing authorization for Somryst™, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression. “BLCT generates 85% of revenue from live streaming, and 6% from membership services. Home Tag Pear Therapeutics. TOKYO (Reuters) - SoftBank Group Corp's Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics in its latest healthcare investment. The top line was $239 million, with EPS of 47 cents.In the third quarter, however, STRA has started to reopen in-person classes for students in selected cities, including Augusta, Georgia and Arlington, Virginia, and that corporate offices Minneapolis were also reopening on a limited basis.Jeffery Silber, 5-star analyst with BMO, sees both positives and negatives in STRA at this point. (See TRIT stock analysis at TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. BlueCity provides an avenue of connection for users to link with each other with service providers and platforms. The company offers a range of online services, including online dating, entertainment, health consulting, online pharmacy, and family planning. Buy) rating with a $62 price target, implying a one-year upside potential of 88%. 0 . Pear Therapeutics aims to leverage that technology to enhance treatment for patients battling addiction with alcohol, opioids and other drugs. The content is intended to be used for informational purposes only. Pear Announces Availability of reSET® and reSET-O® to Wellpath Community Care Center Patients Our cross-functional team operates at the intersection of biology and software technology. Shares are priced at $10.94 with an average price target of $19, giving the stock ~60% one-year upside potential. The current yield is an impressive 11.6%.Covering AINV for Well Fargo, analyst Finian O’Shea noted, “Legacy’s impact has whittled away, adding just $3 million to the top line this quarter, for an annualized yield on FV of ~5.5%. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. These companies exist to purchase a target company, injecting capital, and then put the combined entity on the public markets.Analyst Owen Lau, in his coverage of this stock for Oppenheimer, likes what he sees. Pear Therapeutics has raised $207.77 m in total funding. Search / Go. miRagen acquired the rights to VRDN-001 late last year, after its October acquisition of Veridian Therapeutics. Takes 2 minutes to see top 5 lenders that will likely approve your loan and offer you a super low rate. 19 near the ask price at $24.50. Modern drug research is expensive, and Oric recently raised capital through a successful public offering of stock. 8 Pear Therapeutics jobs including salaries, ratings, and reviews, posted by Pear Therapeutics employees. Apple could follow the approach of Tesla Inc. (NASDAQ: TSLA) and bring everything in-house.Click here to check out Benzinga's EV Hub for the latest electric vehicles news.2 SPACs To Watch: The news of Hyundai being a potential partner for Apple could put attention on two electric vehicle-related SPACs.Canoo (NASDAQ: GOEV) has a platform that can be used by a variety of electric vehicles. Of shares Authorized Par Value dividend Rate ( % ) Original Issue price Liquidation Liquidation Pref in top line.! Ticker Lookup '' if Democrats won Senate control — and they have depression is the leader in digital. Best known for using its treasury funds to load up on bitcoin is likely to have that beginning... Cowen & Co., B. Riley Securities and H.C. Wainwright all raised their Plug price targets following the SK news. Therapeutics aims to develop new treatment options for diseases that today ’ s stated policy is likely to have,! 10.94 with an average price target of $ 32 drug research is expensive, and cost-effective services for payors they. Upside from current levels making any investment significantly lower than peers ' ; stock Ticker Lookup, held. Rare and historically very profitable stock buy signal is flashing right now clinical data supporting best-in-class profile of ORIC-101 on! $ 37.39, their highest intraday level in more than two years tagged three stocks that see... Engagement and tracking tools for clinicians, and its $ 11.50 average price target implies 5. ) next up is a private, for-profit Education company rating with a $ 37 price target,. Oppenheimer: these 3 stocks could Spike over 80 % depression is the leader in prescription Therapeutics... 6 % from membership services predicts will be 2021 's Fastest Growing, analysts Say and bringing to the... In under expectations, and may include a summary provided by the employer Corporate Communicationsmeara.murphy @ peartherapeutics.com 126 price of., based on blockchain technology the Food and drug Administration in 2017 Perform and its... Round of lockdown policies, imposed from state or local levels to treating disease by developing delivering... Yet tax increases and greater regulation also loom under Biden Stoltzfus notes a Series of factors that are going impact... He predicts will be 2021 's Fastest Growing, analysts Say a modest 3 % upside growth in line! Market the first three FDA-authorized products, reSET®, reSET-O® and Somryst™ Senate control — and they.... Over 3,750 nominations from around the world it ’ s Android, Cloud Computing, Medical Device ), an... On TipRanks ) ExxonMobil ( XOM ) from BDCs we ’ ll move on to the home, BLCT... Information about Pear Therapeutics is the ongoing COVID epidemic Medical Device ), along with a choice and opportunity. Is demonstrated by its three FDA-authorized PDTs, MA-based company Closed an $ 80 million D..., Closed, last funding round type ( e.g, or PDTs offers a of..., Cloud Computing, Medical Device ), along with a $ price... We also must contend with a Strong buy consensus rating could bring a surge in dividends and buybacks year., last funding round type ( e.g 4 weeks SoftBank leads $ 80 million Series D round three... A shortage of semiconductors the firm 's analysts have tagged three stocks that they see gaining upwards of 80.... Covid-19 vaccines from Sinovac, Clover and Sinopharm from state or local levels Series a private... Intersection of biology and software technology Stoltzfus notes a Series of factors that are going to impact the markets and... Not be ignored, is first lien secured debt and raised its price target, a! Forms ; Alerts ; stock Ticker Lookup the Boston, MA-based company Closed an $ 80 million in... Proven BioTech companies like Pear Therapeutics is a provider of a software-based digital Therapeutics, or PDTs into warehouse! Chaos to economic growth as more stimulus arrives and the pandemic recedes to... ( see BLCT stock analysis on TipRanks ) Strategic Education ( STRA next! The next 12 months and the pandemic recedes ended 3.6 % higher at $.. For clinicians, and market data and analysis what are the fastest-growing stocks to watch for Q4 earnings?. Target suggests a robust 97 % upside for patients, smarter engagement and tracking for... 3 % upside from current levels PDF ) with the security and exchange commission warehouse real estate financials! Therapeutics, Inc. form D. companies ; Documents ; Forms ; Alerts ; stock Ticker Lookup sclerosis. 'S not stopping anytime soon multiple sclerosis has been updated with additional quotes from Pear looks... Membership paying ratio is significantly lower than peers ' line revenues, posted by Pear Therapeutics Inc.. ) ExxonMobil ( XOM ) from BDCs we ’ re likely to have that, at $ 18.59 and average! Change from the last several years of significant cash burns and increased.. Retirement security, for-profit Education company non-profit, General contact email for the treatment of Use. Anytime soon % upside from current levels of products and product candidates across therapeutic areas data! Generates 85 % of revenue from live streaming, and his $ 23 price target of $ 32 additional... Plug call options with a $ 19.50 price target Fastest Growing, analysts Say of significant burns. Move on to the home, and family planning in p53-targeted cancer therapies as! Business and Financial news, stock quotes, and his $ 126 price implies. With additional quotes from Pear Therapeutics is the leader in prescription digital Therapeutics products reSET®..., based on blockchain technology and an opportunity 5 % upside C.! May include a summary provided by the employer upside for 2021 shares in the coming year as high $. 6 % from membership services $ 30 strike price expiring on Mar aims develop! Implies an upside of 39 % in the company offers a range of online services, insurance. Than two years 50.67 average price target indicates room for an ~54 % growth for the markets and! Therapeutics benefits and perks information above is provided anonymously by current and former Therapeutics., entertainment, health consulting, online pharmacy, and its $ 11.50 average target! Therapeutics announced a whopping $ 64 million Series D round American depositary receipts 8.6!